A Phase II Study to Evaluate ALG-010133 for the Treatment of Chronic Hepatitis B (CHB)
Latest Information Update: 12 Jan 2022
At a glance
- Drugs ALG 010133 (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Aligos Therapeutics
- 06 Jan 2022 According to an Aligos Therapeutics media release, the company and Study Review Committee (SRC) jointly concluded that data from phase 1 study were not sufficient to support further development of ALG-010133 and that dosing should be discontinued. The company has halted further development of ALG-010133 to address chronic hepatitis B.
- 06 Jan 2022 Status changed from planning to withdrawn prior to enrolment, according to an Aligos Therapeutics media release.
- 21 Jun 2021 New trial record